GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NxStage Medical Inc (NAS:NXTM) » Definitions » Financial Strength

NxStage Medical (NxStage Medical) Financial Strength : 0 (As of Sep. 2018)


View and export this data going back to 2005. Start your Free Trial

What is NxStage Medical Financial Strength?

NxStage Medical has the Financial Strength Rank of 0.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

NxStage Medical's Interest Coverage for the quarter that ended in Sep. 2018 was 18.29. NxStage Medical's debt to revenue ratio for the quarter that ended in Sep. 2018 was 0.03. As of today, NxStage Medical's Altman Z-Score is 0.00.


Competitive Comparison of NxStage Medical's Financial Strength

For the Medical Instruments & Supplies subindustry, NxStage Medical's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NxStage Medical's Financial Strength Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NxStage Medical's Financial Strength distribution charts can be found below:

* The bar in red indicates where NxStage Medical's Financial Strength falls into.



NxStage Medical Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

NxStage Medical's Interest Expense for the months ended in Sep. 2018 was $-0.1 Mil. Its Operating Income for the months ended in Sep. 2018 was $1.3 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2018 was $11.2 Mil.

NxStage Medical's Interest Coverage for the quarter that ended in Sep. 2018 is

Interest Coverage=-1*Operating Income (Q: Sep. 2018 )/Interest Expense (Q: Sep. 2018 )
=-1*1.262/-0.069
=18.29

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

NxStage Medical's Debt to Revenue Ratio for the quarter that ended in Sep. 2018 is

Debt to Revenue Ratio=Total Debt (Q: Sep. 2018 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2.097 + 11.209) / 432.488
=0.03

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

NxStage Medical has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NxStage Medical  (NAS:NXTM) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

NxStage Medical has the Financial Strength Rank of 0.


NxStage Medical Financial Strength Related Terms

Thank you for viewing the detailed overview of NxStage Medical's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


NxStage Medical (NxStage Medical) Business Description

Traded in Other Exchanges
N/A
Address
NxStage Medical develops and manufactures products and services for patients with chronic or acute kidney failure. The firm operates in three segments: System One, In-Center, and Services. The System One segment contributes the majority of revenue. It sells and rents the System One portable hemodialysis systems and related consumable products for home and critical care hemodialysis treatments. The In-Center segment sells blood tubing sets and needles for hemodialysis, primarily to dialysis clinics. This business has a high degree of customer concentration. The Services business provides dialysis to customers at NxStage Kidney Care dialysis centers. NxStage generates the majority of its revenue in the United States.
Executives
Earl R Lewis director C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Craig W Moore director C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Jeffrey H Burbank director, officer: Chief Executive Officer NXSTAGE MEDICAL INC, 439 SOUTH UNION STREET 5TH FLOOR, LAWRENCE MA 01843
James J Peters director C/O NXSTAGE MEDICAL, INC., 350 MERRIMACK STREET, LAWRENCE MA 01843
Heyward R Donigan director 452 DISCOVERY ROAD, VIRGINIA BEACH VA 23451
Jean K Mixer director C/O NXSTAGE MEDICAL, INC., 350 MERRIMACK STREET, LAWRENCE MA 01843
Kevin Hershberger officer: Chief Accounting Officer 350 MERRIMACK STREET, LAWRENCE MA 01843
Philippe O. Chambon director C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036
Deerfield Management Company, L.p. (series C) 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Mgmt L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Partners, L.p. 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Special Situations Fund, L.p. 10 percent owner, other: Possible Member of 10% Group 780 3RD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield International Master Fund, L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Special Situations International Master Fund, L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017

NxStage Medical (NxStage Medical) Headlines